Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Telomir Pharmaceuticals, Inc. Common Stock
TELOTelomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida. Address: 100 SE 2nd St., Miami, FL, United States, 33131
Analytics
Precio Objetivo de WallStreet
12.15 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave TELO
Análisis de dividendos TELO
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout TELO
Valoración de la acción TELO
Finanzas TELO
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |